{{Rsnum
|rsid=6823379
|Chromosome=4
|position=41709845
|Orientation=plus
|GMAF=0.1524
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 12.5 | 87.5
| HCB | 1.5 | 21.9 | 76.6
| JPT | 2.7 | 28.3 | 69.0
| YRI | 17.8 | 51.4 | 30.8
| ASW | 7.3 | 41.8 | 50.9
| CHB | 1.5 | 21.9 | 76.6
| CHD | 0.9 | 20.4 | 78.7
| GIH | 1.0 | 10.9 | 88.1
| LWK | 14.5 | 46.4 | 39.1
| MEX | 0.0 | 6.9 | 93.1
| MKK | 7.2 | 46.7 | 46.1
| TSI | 1.0 | 16.7 | 82.4
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs6823379
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.11, combined P value= 6.24E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470248
}}

{{PMID Auto
|PMID=17903293
|Title=Genome-wide association with select biomarker traits in the Framingham Heart Study.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs6823379
|overall_frequency_n=30
|overall_frequency_d=128
|overall_frequency=0.234375
|n_genomes=20
|n_genomes_annotated=0
|n_haplomes=24
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | Illumina Human 1M}}